Vaccine Info

mRNA-1653 hMPV+PIV3 Vaccine

Authored by
Fact checked by
Robert Carlson, MD

mRNA-1653 Vaccine Description

mRNA-1653 is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology.

mRNA-1653 Vaccine Indication

mRNA-1653 is designed to protect against human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections. 

mRNA-1653 Vaccine News

September 17, 2020 - Moderna reported the First 10 pediatric patients dosed in Phase 1 study of hMPV/PIV3 vaccine (mRNA-1653). Sites have re-opened and are actively recruiting participants. Moderna owns worldwide commercial rights to mRNA-1653.

mRNA-1653 Vaccine Clinical Trials

Clinical Trial NCT03392389:  Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

  • This clinical study will assess the safety, reactogenicity, and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.  

Clinical Trials

No clinical trials found